2026-09-01 FDA Warning Letter: Happy Farm Botanicals, Inc. Cited for CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Key takeaway: The FDA Center for Drug Evaluation and Research issued a warning letter (Reference 320-26-121) to Happy Farm Botanicals, Inc., Hyattsville, MD on September 1, 2026, following an inspection conducted March 30–April 2, 2026, citing Current Good Manufacturing Practice (CGMP) violations under 21 CFR parts 210 and 211. The primary violation documented was the firm's failure to conduct identity testing on active pharmaceutical ingredients and other drug components prior to manufacturing over-the-counter drug products, and failure to validate supplier test analyses at appropriate intervals, resulting in adulterated drug products under the Federal Food, Drug, and Cosmetic Act. The FDA rejected the firm's April 22, 2026 response as inadequate and required a comprehensive independent review of the material system including supplier qualification, quality assessment of all incoming materials, and detailed specifications for chemical and microbiological testing of each component lot.
Argus analysis
# FDA Warning Letter Analysis: Happy Farm Botanicals, Inc.
Happy Farm Botanicals, Inc., a manufacturer of over-the-counter drug products located in Hyattsville, Maryland, received a warning letter dated September 1, 2026, from the FDA's Center for Drug Evaluation and Research (CDER). An FDA inspection conducted March 30–April 2, 2026, identified significant Current Good Manufacturing Practice (CGMP) violations that rendered the firm's drug products adulterated under federal law. The inspection documented failures across multiple critical manufacturing and quality functions.
The warning letter cites violations of 21 CFR Parts 210 and 211, the foundational CGMP regulations for finished pharmaceuticals. Specifically, the FDA identified three major deficiencies: (1) failure to perform identity testing on incoming active pharmaceutical ingredients and components per 21 CFR 211.84(d)(1) and (d)(2), including inadequate supplier qualification; (2) failure to establish an adequate stability testing program per 21 CFR 211.166(a) to support labeled expiration dates, with missing data and uninvestigated test failures; and (3) failure of the quality unit to exercise adequate oversight per 21 CFR 211.22, including lack of process validation and inadequate response to recurring equipment failures. These citations address fundamental requirements that ensure drug products meet safety, identity, and potency standards throughout their shelf life.
Happy Farm Botanicals submitted responses to the Form FDA 483 on April 22, 2026, which the FDA found inadequate. Compliance officers should expect CDER to issue a follow-up communication requiring comprehensive remediation plans within a specified timeframe. Peers in botanical and OTC drug manufacturing should monitor whether the company implements independent audits of its supplier qualification program, develops stability-indicating test methods, and establishes robust quality oversight systems. Failure to adequately address these violations may result in seizure, injunction, or import detention actions.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Happy Farm Botanicals, Inc. MARCS-CMS 731926 — September 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-26-121 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Hamed Alaghebandian Recipient Title President Happy Farm Botanicals, Inc. 3708 West Street Hyattsville , MD 20785 United States (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States September 1, 2026 WARNING LETTER Reference number: 320-26-121 To Mr. Hamed Alaghebandian: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, Happy Farm Botanicals, Inc., FDA Establishment Identifier (FEI) 3011407349, at 3708 West Street, Hyattsville, from March 30 to April 2, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your April 22, 2026, response to our Form FDA 483 in detail. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)). Your firm manufactures over-the-counter (OTC) drug products, including (b)(4) . Your firm failed to perform identification testing on raw materials and components, incl…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Happy Farm Botanicals, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Happy Farm Botanicals, Inc. as of 2026-09-08. Argus ingests new FDA enforcement records daily.
- What FDA violations was Happy Farm Botanicals, Inc. cited for?
- The FDA Warning Letter to Happy Farm Botanicals, Inc. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Happy Farm Botanicals, Inc.?
- FDA issued the letter (MARCS-CMS 731926) on 2026-09-01 and posted it publicly on fda.gov on 2026-09-08.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-09-01 FDA Warning Letter: Happy Farm Botanicals, Inc. Cited for CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-happy-farm-botanicals-inc-2026-09-01-cgmp
"2026-09-01 FDA Warning Letter: Happy Farm Botanicals, Inc. Cited for CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-happy-farm-botanicals-inc-2026-09-01-cgmp.
Argus HQ Research. "2026-09-01 FDA Warning Letter: Happy Farm Botanicals, Inc. Cited for CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed September 9, 2026. https://argushq.ai/fda/warning-letter/fda-wl-happy-farm-botanicals-inc-2026-09-01-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_happy_farm_botanicals_inc_2026_09_01_cgmp_2026,
title = {2026-09-01 FDA Warning Letter: Happy Farm Botanicals, Inc. Cited for CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-happy-farm-botanicals-inc-2026-09-01-cgmp},
note = {Accessed: September 9, 2026}
}